EXHIBIT 99.1

GENOIL INC.

March 31, 2023

FORM 6-K

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

		Page
Consolidated Balance Sheets as of March 31, 2023 and December 31, 2022		F-2
Consolidated Statements of Operations for the three months ended March 31, 2023 and March 31, 2022		F-3
Consolidated Statements of Stockholders’ Deficit for the three months ended March 31, 2023 and March 31, 2022		F-4
Consolidated Statements of Cash Flows for the three months ended March 31, 2023 and March 31, 2022		F-5
Notes to Consolidated Financial Statements		F-6

F-1

Table of Contents

GENOIL INC.
Consolidated Balance Sheets
(Expressed in US Dollars)

ASSETS

	March 31,			December 31,
	2023			2022
	(Unaudited)

CURRENT ASSETS
Cash and cash equivalents	$	5,830		$	5,044
Due from related-parties		281,433			273,248
Prepaid expenses and other current assets		4,568			4,387

Total Current Assets		291,831			282,679

Land located in Alberta Canada		43,163			43,163

OTHER ASSETS
Intangible assets, net		1			1

TOTAL ASSETS	$	334,995		$	325,843

LIABILITIES AND STOCKHOLDERS' DEFICIT

CURRENT LIABILITIES
Trade and other payables	$	105,141		$	115,342
Accrued interest payable, to related parties		5,952,495			5,628,495
Convertible notes, current portion		-			5,327,920
Due to related parties		46,875			46,875

Total Current Liabilities		6,104,511			11,118,632

NON-CURRENT LIABILITIES
Convertible notes, non current portion		5,327,920			-

Total Non-Current Liabilities		5,327,920			-

TOTAL LIABILITIES		11,432,431			11,118,632

STOCKHOLDERS' DEFICIT
Preferred Stock, no par value; authorized 10,000,000 shares, issued and 00outstanding 0 and 0 shares, respectively		-			-
Common Stock, no par value; issued and outstanding 709,013,029 and 00696,013,029 shares, respectively		51,600,944			51,470,944
Contributed surplus		39,386,095			37,297,127
Accumulated other comprehensive income (loss)		(221,860	)		(221,860	)
Accumulated deficit		(101,862,615	)		(99,339,000	)

Total Stockholders' Deficit		(11,097,436	)		(10,792,789	)

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$	334,995		$	325,843

The accompanying notes are an intergral part of these consolidated financial statements

F-2

Table of Contents

GENOIL INC.
Consolidated Statements of Operations
(Expressed in US Dollars)
(Unaudited)

	Three months ended March 31,
	2023			2022
				(As Restated - see Note 11)

REVENUES	$	-		$	-
COST OF SALES		-			-

GROSS PROFIT		-			-

OPERATING EXPENSES
Stock based compensation to officers, directors, and consultants		2,097,468			1,156,162
Other Operating Expenses		102,148			89,321
Total Operating Expenses		2,199,616			1,245,483

LOSS FROM OPERATIONS		(2,199,616	)		(1,245,483	)

Other Income (Expense)
Finance expense (as restated for the three months ended March 31, 2022 00- see Note 11)		(323,999	)		(266,981	)

Total Other Income (Expense) - Net		(323,999	)		(266,981	)

INCOME (LOSS) BEFORE INCOME TAXES (as restated for the 00three months ended March 31, 2022 - see Note 11)		(2,523,615	)		(1,512,464	)
PROVISION FOR INCOME TAXES		-			-

NET INCOME (LOSS) (as restated for the three months ended 00March 31, 2022 - see Note 11)		(2,523,615	)		(1,512,464	)

Deemed dividends for warrants		-			(780	)

NET INCOME (LOSS) ATTRIBUTABLE TO COMMON 00SHAREHOLDERS (as restated for the three months ended 00March 31, 2022 - see Note 11)	$	(2,523,615	)	$	(1,513,244	)

Weighted average shares outstanding - Basic and Diluted		701,969,696			647,258,696

NET LOSS PER SHARE - Basic and Diluted	$	0.00		$	0.00

The accompanying notes are an intergral part of these consolidated Financial Statements

F-3

Table of Contents

GENOIL INC.
Consolidated Statements of Stockholders' Deficit
(Expressed in US Dollars)
(Unaudited)

	Common		Share		Contributed		Accumulated Other Comprehensive Income			Accumulated			Total Stockholders'
	Shares		Capital		Surplus		(Loss)			Deficit			Deficit
Balance as of January 1, 2022		640,633,029	$	50,917,144	$	36,151,385	$	(221,860	)	$	(95,761,361	)	$	(8,914,692	)
Sale of common shares (and warrants) in private placements		11,630,000		116,300		-		-			-			116,300
Issuance of common shares for services		1,120,000		11,200		-		-			-			11,200
Stock based compensation		-		-		1,144,962		-			-			1,144,962
Deemed Dividends		-		-		780					(780	)		-
Net loss for the three-months ended March 31, 2022 (as restated - see Note 11)											(1,512,464	)		(1,512,464	)
Balance as of March 31, 2022 (as restated - see Note 11)		653,383,029	$	51,044,644	$	37,297,127	$	(221,860	)	$	(97,274,605	)	$	(9,154,694	)

Balance as of January 1, 2023		696,013,029		51,470,944		37,297,127		(221,860	)		(99,339,000	)		(10,792,789	)
Sale of common shares (and warrants) in private placements		11,800,000		118,000		-		-			-			118,000
Issuance of common shares for services		1,200,000		12,000		-		-			-			12,000
Stock based compensation		-		-		2,088,968		-			-			2,088,968
Deemed Dividends		-		-		-		-			-			-
Net loss for the three-months ended March 31, 2023											(2,523,615	)		(2,523,615	)
Balance as of March 31, 2023		709,013,029		51,600,944		39,386,095		(221,860	)		(101,862,615	)		(11,097,436	)

The accompanying notes are an intergral part of these consolidated Financial Statements

F-4

Table of Contents

GENOIL INC. Consolidated Statements of Cash Flows (Expressed in US Dollars) (Unaudited)

	Three months ended March 31,
	2023			2022
				(As Restated - see Note 11)

OPERATING ACTIVITIES
Net income (loss) (as restated for the three months ended March 31, 2022 - see Note 11)	$	(2,523,615	)	$	(1,512,464	)
Adjustments to reconcile net loss
to cash flows used in operating activities:
Stock based compensation		2,100,968			1,156,162

Changes in operating assets and liabilities
Prepaid expenses and other current assets		(181	)		3,226
Accrued interest payable (as restated for the three months ended March 31, 2022 - see 00Note 11)		324,000			266,981
Trade and other payables		(10,201	)		(11,059	)

Net Cash Used in Operating Activities		(109,029	)		(97,154	)

FINANCING ACTIVITIES
Net change in related party receivables		(8,185	)		(18,501	)
Net change in related party payables		-			-
Cash received from equity investors		118,000			116,300

Net cash provided by Financing Activities		109,815			97,799

Increase (Decrease) in Cash		786			645
Cash at beginning of year		5,044			12

Cash at end of period	$	5,830		$	657

Supplemental disclosure of cash flow information

Interest Paid	$	-		$	-
Income taxes paid	$	-		$	-
Deemed dividends related to issuance of warrants.	$	-		$	780

The accompanying notes are an intergral part of these consolidated Financial Statements

F-5

Table of Contents

Genoil INC.

Notes to Consolidated Financial Statements

For the Three Months Ended March 31, 2023 and March 31, 2022

(Expressed in US Dollars)

(Unaudited)

1. REPORTING ENTITY AND GOING CONCERN

Genoil Inc. (“Genoil”) was incorporated under the Canada Business Corporations Act in September 1996. The consolidated financial statements of Genoil Inc. comprise Genoil Inc. and its subsidiaries, Genoil USA Inc., Genoil Emirates LLC (“Emirates LLC”) and Two Hills Environmental Inc. (“Two Hills”) (collectively the “Company”). The Company is a technology development company focused on providing innovative solutions to the oil and gas industry through the use of proprietary technologies. The Company’s business activities are primarily directed to the development and commercialization of its upgrader technology, which is designed to economically convert heavy crude oil into light synthetic crude. The Company is quoted on the OTC Markets under the symbol GNOLF. The Company’s registered address is care of Bennett Jones LLP, Suite 4500, 855 - 2^nd Street SW, Calgary, Alberta.

These consolidated financial statements have been presented on a going concern basis. The Company reported net losses of $2,523,615 and $1,512,464 for the three months ended March 31, 2023 and 2022, respectively. The Company used funds in operating activities of $109,029 and $97,154 for the three months ended March 31, 2023 and 2022, respectively. The Company had a net working capital deficiency of $5,812,680 and $10,835,953 at March 31, 2023 and December 31, 2022, respectively. The Company had a stockholders’ deficit of $11,097,436 and $10,792,789 at March 31, 2023 and December 31, 2022, respectively. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

The ability of the Company to continue as a going concern is dependent on commercializing its technologies, achieving profitable operations and obtaining the necessary financing in order to develop these technologies further. The outcome of these matters cannot be predicted at this time. The Company will continue to review the prospects of raising additional debt and equity financing to support its operations until such time that its operations become self-sustaining, to fund its research and development activities and to ensure the realization of its assets and discharge of its liabilities. While the Company is expanding its best efforts to achieve the above plans, there is no assurance that any such activity will generate sufficient funds for future operations.

The Company is not expected to be profitable during the ensuing twelve months and therefore must rely on securing additional funds from either issuance of debt or equity financing for cash consideration. During the three months ended March 31, 2023 and 2022, the Company received net proceeds of $109,815 and $97,799, respectively, pursuant to financing activities.

Management, utilizing close personal relationships, has been successful in raising capital through periodic private placements of the Company’s common shares. Although these shares are subject to a “hold” period on the United States stock markets, the investors’ confidence in the undertakings of management, with respect to future positive market performance of the Company’s common stock, permits this avenue of financing to exist. External sources of debt financing are not available to the Company due to its precarious financial position.

The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets and classification of liabilities that might be necessary should the Company be unable to continue its operations. Such adjustments could be material.

F-6

Table of Contents

2. SIGNIFICANT ACCOUNTING POLICIES

The accounting policies set out below have been applied consistently to all periods presented in these consolidated financial statements.

(a) Principles of Consolidation:

The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States and incorporate the financial statements of Genoil and entities controlled by it. Control is achieved where Genoil has the power to govern the financial and operating policies of an entity so as to obtain benefits from its activities.

Genoil has the following subsidiaries:

	·	Genoil USA Inc., incorporated in Delaware, United States, which is a wholly owned subsidiary of Genoil.
	·	Genoil Emirates LLC, incorporated in the United Arab Emirates, which will focus upon the fields of oil and water processing and treatment in the United Arab Emirates. Genoil Emirates LLC is jointly owned by S.B.K. Commercial Business Group LLC and Genoil. As of March 31, 2023, Emirates LLC had not yet commenced operations and holds no assets.
	·	Two Hills Environmental Inc., incorporated in Canada and registered in Alberta, which is a wholly owned subsidiary of Genoil. Two Hills was formed to enter into the oilfield waste disposal industry by capitalizing upon its current undeveloped asset base. The asset base comprises a site under which three salt caverns have been formed in the Lotsberg Formation beneath the earth’s surface. Such caverns are used in the oilfield disposal industry as a destination for oilfield wastes.

The financial results of Genoil’s subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control ceases. The accounting policies of subsidiaries have been changed where necessary to align them with the policies adopted by Genoil.

Intercompany balances and transactions, and any unrealized income and expenses arising from intercompany transactions, are eliminated in preparing the consolidated financial statements.

(b) Interim Financial Statements

The unaudited consolidated financial statements of the Company for the three months ended March 31, 2023 and 2022 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and pursuant to the requirements for reporting on Form 10-Q and Regulation S-K. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. However, such information reflects all adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of the management, necessary for the fair presentation of the financial position and the results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full fiscal year. The balance sheet information as of December 31, 2022 was derived from the audited financial statements included in the Company’s financial statements as of and for the year ended December 31, 2022 included in the Company’s Report of Form 20-F filed with the Securities and Exchange Commission (the “SEC”) on May 2, 2023. These financial statements should be read in conjunction with that report.

The reporting currency of the Company is the United States Dollar. The functional currency of Genoil and its subsidiaries is the United States Dollar. Transactions denominated in currencies other than the functional currency are translated at the exchange rates prevailing at the dates of the transactions. Exchange gains and losses are reflected in income.

F-7

Table of Contents

(d) Use of estimates and judgments

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. By their nature, judgments, estimates and assumptions are subject to measurement uncertainty and changes in such judgments, estimates and assumptions in future periods could result in a material change in future financial statements. Actual results may differ from these estimates.

Judgment is used in situations where there is a choice or assessment required by management. Estimates and underlying assumptions are required on an ongoing basis and revisions are recognized in the year in which such estimates are revised.

(e) Cash and cash equivalents

The Company considers all short-term investments with original maturities of three months or less to be cash equivalents.

(f) Stock-based compensation

The Company grants common stock, stock options, and Price Appreciation Certificates to employees, directors, and consultants for various services rendered to the company. Share-based payments to these individuals are measured at the fair value of the securities issued and amortized over the vesting periods. The amount recognized as a share-based payment expense during a reporting period is adjusted to reflect the number of awards expected to vest. The offset to this recorded cost is to contributed surplus. A forfeiture rate is estimated on the grant date and is subsequently adjusted to reflect the actual number of options that vest. At the time of exercise, the consideration and related contributed surplus recognized to the exercise date are credited to share capital.

(g) Income tax

Income tax expense comprises current and deferred tax. Income tax expense is recognized in profit or loss except to the extent that it relates to items recognized directly in equity, in which case it is recognized in equity.

Current tax is the expected tax payable on the taxable income for the period, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax payable in respect of previous years.

Deferred tax is recognized using the liability method, providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is not recognized on the initial recognition of assets or liabilities in a transaction that is not a business combination. In addition, deferred tax is not recognized for taxable temporary differences arising on the initial recognition of goodwill. Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realized simultaneously.

A deferred tax asset is recognized to the extent that it is probable that future taxable profits will be available against which the temporary difference can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized.

F-8

Table of Contents

(h) Loss per share

Basic earnings (loss) per share is calculated by dividing the income (loss) attributable to common shareholders of the Company by the weighted average number of common shares outstanding during the period. Diluted earnings (loss) per share is determined by adjusting the income (loss) attributable to common shareholders and the weighted average number of common shares outstanding for the effects of dilutive instruments such as convertible notes, stock options and warrants. The calculation assumes the proceeds on exercise of options and warrants are used to repurchase shares at the current market price. All options and warrants are anti-dilutive when the Company is in a loss position.

(i) Recent accounting pronouncements:

The Company has evaluated recent accounting pronouncements and their adoption has not had or is not expected to have a material impact on the Company’s financial position or operations.

3. DETERMINATION OF FAIR VALUES

A number of the Company’s accounting policies and disclosures require the determination of fair value, for both financial and non-financial assets and liabilities. When applicable, further information about the assumptions made in determining fair values is disclosed in the notes specific to that asset or liability. The Company is required to classify fair value measurements using a hierarchy that reflects the significance of the inputs used in making the measurements.

The fair value hierarchy is as follows:

	·	Level 1 – quoted prices in active markets for identical assets or liabilities;

	·	Level 2 – inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly; and,

	·	Level 3 – inputs for the asset or liability that are not based on observable market data.

Cash and cash equivalents have been measured using level 1 inputs.

The fair value of cash and cash equivalents, due from related parties, trade and other payables, accrued interest payable, convertible notes, and due to related parties approximates their carrying value due to their short term to maturity.

The fair values of stock options and Price Appreciation Certificates are measured using the Black-Scholes pricing model. Measurement inputs include share price on measurement date, exercise price of the instrument, expected forfeiture rate (based on historic forfeitures), expected volatility (based on weighted average historic volatility adjusted for changes expected due to publicly available information), weighted average expected life of the instruments (based on historical experience and general option holder behavior), expected dividends, and the risk-free interest rate.

F-9

Table of Contents

4. DUE FROM RELATED PARTIES

Due from related parties consist of:

	March 31,		December 31,
Borrower	2023		2022
Lifschultz Enterprise Company LLC (an entity controlled by David Lifschultz, Genoil chief executive officer, and Bruce Abbott, Genoil chief operating officer)	$	281,433	$	273,248
Totals	$	281,433	$	273,248

The receivable is non-interest bearing and is due on demand.

5. ACCRUED INTEREST PAYABLE TO RELATED PARTIES

Accrued interest payable to related parties consist of:

	March 31,		December 31,
Lender	2023		2022
Lifschultz Enterprise Company LLC	$	2,993,424	$	2,858,683
Sidney B. Lifschultz 1992 Family Trust (an entity controlled by David Lifschultz)		1,081,034		1,032,374
David Lifschultz		939,033		868,733
Bruce Abbott		939,004		868,705
Totals	$	5,952,495	$	5,628,495

The accrued interest payable relates to the convertible notes outstanding (see Note 6).

6. CONVERTIBLE NOTES

Convertible notes consist of:

	March 31,		December 31,
Lender	2023		2022
Lifschultz Enterprise Company LLC	$	1,695,053	$	1,695,053
Sidney B. Lifschultz 1992 Family Trust		612,146		612,146
David Lifschultz		1,510,368		1,510,368
Bruce Abbott		1,510,353		1,510,353
Totals		5,327,920		5,327,920
Current portion		-		(5,327,920	)
Non-current portion	$	5,327,920	$	-

The notes bear interest at 12% compounded semi-annually and their maturity was extended on April 27, 2020 to April 27, 2022 and effective January 1, 2023 to January 1, 2026. The notes are convertible into shares of Genoil common stock at a price of $0.01 per share. The notes are secured by the assets of the Company.

F-10

Table of Contents

The notes provide that in the event that the inflation rate (based on the US CPI) exceeds 3%, the principal and accrued interest balances are increased by such inflation rate. Effective December 31, 2021, this inflation protection provision was triggered. The principal balances were increased 4.698% or a total of $221,358 (from $4,711,764 to $4,933,122) and the accrued interest balances were increased 4.698% or a total of $183,770 (from $3,911,705 to $4,095,475).

Effective December 31, 2022, as a result of the inflation protection provision, the principal balances were increased 8.003% or a total of $394,798 (from $4,933,122 to $5,327,920) and the accrued interest balances were increased 8.003% or a total of $417,071 (from $5,211,424 to $5,628,495). The $811,869 total increase in the principal and accrued interest balances has been included in finance expense in the consolidated statement of operations for the three months and year ended December 31, 2022.

7. DUE TO RELATED PARTIES

Due to related parties consist of:

	March 31,		December 31,
Creditor	2023		2022
Occupancy costs payable to Bruce Abbott and David Lifschultz for use of Mamaroneck New York property from January 1, 2018 to September 30, 2020	$	46,875	$	46,875
Totals	$	46,875	$	46,875

The payables are non-interest bearing and are due on demand.

8. SHARE CAPITAL

Preferred Stock

There are 10,000,000 shares of Class A Preferred Stock authorized but none are outstanding.

Common Stock

There are an unlimited number of shares of common stock, no par value, authorized to be issued.

During the first quarter of 2022, the Company sold a total of 11,630,000 shares of common stock (and warrants) in private placements for total proceeds of $116,300.

During the first quarter of 2022, the Company issued a total of 1,120,000 shares of common stock as compensation for services. The fair value of the shares issued (at dates of issuance) totaled $11,200.

During the first quarter of 2023, the Company sold a total of 11,800,000 shares of common stock (and warrants) in private placements for total proceeds of $118,000.

During the first quarter of 2023, the Company issued a total of 1,200,000 shares of common stock as compensation for services. The fair value of the shares issued (at dates of issuance) totaled $12,000.

F-11

Table of Contents

Warrants

In conjunction with the private placements, the Company issued warrants to purchase common stock. The following is a summary of the warrants activity for the period December 31, 2020 to March 31, 2023.

Number outstanding at December 31, 2020	130,668,838
Granted	40,015,000
Cancelled	(20,140,700	)
Number outstanding at December 31, 2021	150,543,138
Granted	45,700,000
Cancelled	(21,551,964	)
Number outstanding at December 31, 2022	174,691,174
Granted	11,800,000
Cancelled	(5,130,840	)
Number outstanding at March 31, 2023	181,360,334

At March 31, 2023, the 181,360,334 warrants outstanding had a weighted average exercise price of $0.03 per share, a weighted average remaining contractual life of 2.69 years, and an aggregate intrinsic value of $0.

Deemed Dividends related to issuance of warrants

During the first quarter of 2022, the Company granted a total of 60,000 warrants to certain investors as deemed dividends. The fair value of the warrants (at dates of issuance) totaled $780 and was estimated using the Black-Scholes options pricing model based on the following assumptions: (1) stock prices of $0.01 per share, (2) exercise prices of $0.025 per share, (3) expected volatility of 368.5%, (4) expected term of 5 years, (5) risk-free interest rate of 1.62%, and (6) dividend rate of 0%.

9. STOCK-BASED COMPENSATION

Stock-based compensation consists of:

	Three Months Ended
	March 31,		March 31,
Type of Security	2023		2022
Price Appreciation Certificates	$	2,026,969	$	1,049,965
Options issued to outside directors and consultants		61,999		94,997
Common stock issued for services		8,500		11,200
Totals	$	2,097,468	$	1,156,162

F-12

Table of Contents

The following is a summary of the compensatory securities activity for the period December 31, 2020 to March 31, 2023:

Common stock equivalent	Price Appreciation Certificates			Options			Total
Number outstanding at December 31, 2018		362,400,000			33,140,000			395,540,000
Granted		123,700,000			22,950,000			146,650,000
Cancelled		-			-			-
Number outstanding at December 31, 2020		505,400,000			57,140,000			562,540,000
Granted		60,000,000			6,000,000			66,000,000
Cancelled		(15,000,000	)		(5,250,000	)		(20,250,000	)
Number outstanding at December 31, 2021		550,400,000			57,890,000			608,290,000
Granted		105,000,000			9,500,000			114,500,000
Cancelled		(66,000,000	)		(18,190,000	)		(84,190,000	)
Number outstanding at December 31, 2022		589,400,000			49,200,000			638,600,000
Granted		202,700,000			6,200,000			208,900,000
Cancelled		(90,000,000	)		(2,750,000	)		(92,750,000	)
Number outstanding at March 31, 2023		702,100,000			52,650,000			754,750,000

PRICE APPRECIATION CERTIFICATES

In lieu of compensation the Company has entered into agreements (“Price Appreciation Certificates”) with David Lifschultz and Bruce Abbott whereby, at the request of the executives, the Company agrees to pay the equivalent sum of the rise in the Company’s stock price based on the agreed upon number of shares, from a fixed per share amount to the average of the last 10 trading days (volume weighted average price).

The number of shares reflect a potential salary for the two executives that only exist if the price of the shares rise above the price appreciation base amount. The Company has no obligation to pay the two executives if the stock does not rise. The Company, at its exclusive option and benefit, can proceed with a private placement at the share price on the date of exercise and the executive will subscribe to this private placement for the entire sum advanced by the Company.

The Company accounts for these Price Appreciation Certificates as an equity instrument due to its exclusive option to require a subscription to the private placement and expenses the fair value (at date of grant) of the instruments using a Black-Scholes pricing model.

At December 31, 2022, the 589,400,000 Price Appreciation Certificates outstanding had a weighted average exercise price of $0.03 per share, a weighted average remaining contractual life of 2.29 years, and an aggregate intrinsic value of $0.

At March 31, 2023, the 702,100,000 Price Appreciation Certificates outstanding had a weighted average exercise price of $0.02 per share, a weighted average remaining contractual life of 3.16 years, and an aggregate intrinsic value of $0.

OPTIONS

The Company has a stock option plan for directors, officers, employees and consultants. The term and vesting conditions of each option may be fixed by the Board of Directors when the option is granted, but the term cannot exceed 10 years. The maximum number of shares that may be reserved for issuance under the plan is fixed at 69,819,579. The maximum number of shares that may be optioned to any one person is 5% of the shares outstanding at the date of the grant. The options granted in 2022 and 2023 all vested immediately.

F-13

Table of Contents

The fair value of stock options granted during 2023 and 2022 was estimated on the dates of grant using the Black-Scholes pricing model based on the following assumptions:

	2023			2022
Volatility		385.00	%		370.90	%
Expected life	5 years			5 years
Risk-free rate		3.59	%		1.74	%
Dividend yield		-			-
Forfeiture rate		0	%		0	%
Stock Price at Valuation	$	0.01		$	0.01
Exercise Price	$	0.01		$	0.01

At December 31, 2022, the 49,200,000 stock options outstanding had a weighted average exercise price of $0.03 per share, a weighted average remaining contractual life of 2.13 years, and an aggregate intrinsic value of $0.

At March 31, 2023, the 52,650,000 stock options outstanding had a weighted average exercise price of $0.03 per share, a weighted average remaining contractual life of 2.35 years, and an aggregate intrinsic value of $0.

10. INCOME TAXES

The provision for (benefit from) income taxes reflects the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for tax purposes. The provision for (benefit from) income taxes differs from that computed by applying the statutory United States federal income tax rate of 21% for 2023 and 2022 to loss before income taxes. The sources of the differences are as follows:

	Three Months Ended
	2023			2022
Income (loss) before income taxes	$	(2,523,615	)	$	(1,512,464	)
Expected recovery at statutory tax rate	$	529,959		$	317,617
Non-deductible stock-based compensation		(440,468	)		(242,794	)
Increase in valuation allowance		(89,491	)		(74,823	)
Provision for Income Taxes	$	-		$	-

Based on management’s present assessment, the Company has not yet determined that a deferred tax asset attributable to the future utilization of the net operating loss carryforward as of March 31, 2023 will be realized. Accordingly, the Company has maintained a 100% valuation allowance against the deferred tax asset in the financial statements at March 31, 2023. The Company will continue to review this valuation allowance and make adjustments as appropriate.

Current United States income tax laws limit the amount of loss available to be offset against future taxable income when a substantial change in ownership occurs. Therefore, the amount available to offset future taxable income may be limited.

All tax years remain subject to examination by major taxing jurisdictions.

F-14

Table of Contents

11. RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS

The Company has restated the consolidated financial statements at March 31, 2022 and for the three months then ended (which were included in the Company’s Form 6-K filed with the SEC on July 5, 2022) in order to correct the amount of interest expense previously recorded for the three months ended March 31, 2022.

As previously reported, interest expense on the convertible notes was erroneously calculated in the three months ended March 31, 2022 due to the failure to include the December 31,2021 inflation adjustment provided for in the convertible notes (see Note 6). As restated, the Company has correctly recorded interest expense based on balances including the December 31, 2021 inflation adjustment of $405,128.

The effect of the restatement adjustment on the Consolidated Balance Sheet at March 31, 2022 follows:

	As Previously Reported			Restatement Adjustment			As Restated
Total assets	$	288,001		$	-		$	288,001

Accrued interest payable	$	4,166,689		$	195,767		$	4,362,456
Convertible notes		4,711,764			221,358			4,933,122
Other current liabilities		147,117			-			147,117
Non-current liabilitites		-			-			-
Total liabilities		9,025,570			417,125			9,442,695
Total stockholders' deficit		(8,737,569	)		(417,125	)		(9,154,694	)
Total liabilities and stockholders' deficit	$	288,001		$	-		$	288,001

The effect of the restatement adjustment on the Consolidated Statement of Operations for the three months ended March 31, 2022 follows:

	As Previously Reported			Restatement Adjustment			As Restated
Operating expenses	$	1,245,483		$	-		$	1,245,483
Finance expense		254,984			11,997			266,981
Net loss	$	1,500,467		$	11,997		$	1,512,464
Net loss per share basic and diluted	$	(0.00	)	$	(0.00	)	$	(0.00	)

12. SUBSEQUENT EVENTS

From April 1, 2023 to April 30, 2023, the Company sold a total of 4,550,000 shares of common stock (and warrants) in private placements for proceeds of $45,500.

From April 1, 2023 to April 30, 2023, the Company issued a total of 1,200,000 shares of common stock as compensation for services. The fair value of the shares issued (at dates of issuance) totaled $12,000.

F-15

GENOIL INC 6-K